nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Erectile dysfunction—Vincristine—sarcoma	0.00728	0.00728	CcSEcCtD
Lisdexamfetamine—Weight decreased—Vincristine—sarcoma	0.00715	0.00715	CcSEcCtD
Lisdexamfetamine—Hallucination—Thiotepa—sarcoma	0.0071	0.0071	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Mitoxantrone—sarcoma	0.00709	0.00709	CcSEcCtD
Lisdexamfetamine—Hepatitis—Dactinomycin—sarcoma	0.00708	0.00708	CcSEcCtD
Lisdexamfetamine—Depression—Vincristine—sarcoma	0.00703	0.00703	CcSEcCtD
Lisdexamfetamine—Weight increased—Mitoxantrone—sarcoma	0.00701	0.00701	CcSEcCtD
Lisdexamfetamine—Weight decreased—Mitoxantrone—sarcoma	0.00696	0.00696	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Vincristine—sarcoma	0.00695	0.00695	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Vincristine—sarcoma	0.00691	0.00691	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Mitoxantrone—sarcoma	0.00677	0.00677	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Mitoxantrone—sarcoma	0.00673	0.00673	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Dactinomycin—sarcoma	0.0067	0.0067	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00667	0.00667	CcSEcCtD
Lisdexamfetamine—Eye disorder—Thiotepa—sarcoma	0.00667	0.00667	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Thiotepa—sarcoma	0.00662	0.00662	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Thiotepa—sarcoma	0.00645	0.00645	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Thiotepa—sarcoma	0.00643	0.00643	CcSEcCtD
Lisdexamfetamine—Hallucination—Vincristine—sarcoma	0.0063	0.0063	CcSEcCtD
Lisdexamfetamine—Mental disorder—Thiotepa—sarcoma	0.00625	0.00625	CcSEcCtD
Lisdexamfetamine—Malnutrition—Thiotepa—sarcoma	0.00621	0.00621	CcSEcCtD
Lisdexamfetamine—Hepatitis—Mitoxantrone—sarcoma	0.00616	0.00616	CcSEcCtD
Lisdexamfetamine—Dyskinesia—Epirubicin—sarcoma	0.00609	0.00609	CcSEcCtD
Lisdexamfetamine—Nervousness—Thiotepa—sarcoma	0.00603	0.00603	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Vincristine—sarcoma	0.00587	0.00587	CcSEcCtD
Lisdexamfetamine—Vision blurred—Thiotepa—sarcoma	0.00585	0.00585	CcSEcCtD
Lisdexamfetamine—Agitation—Thiotepa—sarcoma	0.00571	0.00571	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Vincristine—sarcoma	0.0057	0.0057	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Etoposide—sarcoma	0.00566	0.00566	CcSEcCtD
Lisdexamfetamine—Dyskinesia—Doxorubicin—sarcoma	0.00563	0.00563	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Etoposide—sarcoma	0.00563	0.00563	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Etoposide—sarcoma	0.0056	0.0056	CcSEcCtD
Lisdexamfetamine—Mental disorder—Vincristine—sarcoma	0.00554	0.00554	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Etoposide—sarcoma	0.0054	0.0054	CcSEcCtD
Lisdexamfetamine—Convulsion—Thiotepa—sarcoma	0.00538	0.00538	CcSEcCtD
Lisdexamfetamine—Hypertension—Thiotepa—sarcoma	0.00536	0.00536	CcSEcCtD
Lisdexamfetamine—Anxiety—Thiotepa—sarcoma	0.00527	0.00527	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00525	0.00525	CcSEcCtD
Lisdexamfetamine—Agitation—Vincristine—sarcoma	0.00506	0.00506	CcSEcCtD
Lisdexamfetamine—Vision blurred—Mitoxantrone—sarcoma	0.00506	0.00506	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Thiotepa—sarcoma	0.00497	0.00497	CcSEcCtD
Lisdexamfetamine—Tachycardia—Thiotepa—sarcoma	0.00495	0.00495	CcSEcCtD
Lisdexamfetamine—Skin disorder—Thiotepa—sarcoma	0.00492	0.00492	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Etoposide—sarcoma	0.00485	0.00485	CcSEcCtD
Lisdexamfetamine—Anorexia—Thiotepa—sarcoma	0.00483	0.00483	CcSEcCtD
Lisdexamfetamine—Anorexia—Dactinomycin—sarcoma	0.0048	0.0048	CcSEcCtD
Lisdexamfetamine—Eye disorder—Etoposide—sarcoma	0.00479	0.00479	CcSEcCtD
Lisdexamfetamine—Convulsion—Vincristine—sarcoma	0.00477	0.00477	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Etoposide—sarcoma	0.00476	0.00476	CcSEcCtD
Lisdexamfetamine—Hypertension—Vincristine—sarcoma	0.00476	0.00476	CcSEcCtD
Lisdexamfetamine—Convulsion—Mitoxantrone—sarcoma	0.00465	0.00465	CcSEcCtD
Lisdexamfetamine—Hypertension—Mitoxantrone—sarcoma	0.00463	0.00463	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Etoposide—sarcoma	0.00463	0.00463	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Etoposide—sarcoma	0.00462	0.00462	CcSEcCtD
Lisdexamfetamine—Anxiety—Mitoxantrone—sarcoma	0.00455	0.00455	CcSEcCtD
Lisdexamfetamine—Somnolence—Thiotepa—sarcoma	0.00451	0.00451	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Vincristine—sarcoma	0.0045	0.0045	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Thiotepa—sarcoma	0.00446	0.00446	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Vincristine—sarcoma	0.00441	0.00441	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Thiotepa—sarcoma	0.00441	0.00441	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Mitoxantrone—sarcoma	0.00438	0.00438	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Thiotepa—sarcoma	0.00438	0.00438	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dactinomycin—sarcoma	0.00437	0.00437	CcSEcCtD
Lisdexamfetamine—Fatigue—Thiotepa—sarcoma	0.00437	0.00437	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Vincristine—sarcoma	0.00435	0.00435	CcSEcCtD
Lisdexamfetamine—Fatigue—Dactinomycin—sarcoma	0.00434	0.00434	CcSEcCtD
Lisdexamfetamine—Constipation—Thiotepa—sarcoma	0.00434	0.00434	CcSEcCtD
Lisdexamfetamine—Anorexia—Vincristine—sarcoma	0.00428	0.00428	CcSEcCtD
Lisdexamfetamine—Tachycardia—Mitoxantrone—sarcoma	0.00427	0.00427	CcSEcCtD
Lisdexamfetamine—Skin disorder—Mitoxantrone—sarcoma	0.00425	0.00425	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Epirubicin—sarcoma	0.00424	0.00424	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Mitoxantrone—sarcoma	0.00423	0.00423	CcSEcCtD
Lisdexamfetamine—Anorexia—Mitoxantrone—sarcoma	0.00417	0.00417	CcSEcCtD
Lisdexamfetamine—Diplopia—Epirubicin—sarcoma	0.00415	0.00415	CcSEcCtD
Lisdexamfetamine—Affect lability—Epirubicin—sarcoma	0.00409	0.00409	CcSEcCtD
Lisdexamfetamine—Insomnia—Vincristine—sarcoma	0.00407	0.00407	CcSEcCtD
Lisdexamfetamine—Urticaria—Thiotepa—sarcoma	0.00403	0.00403	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Thiotepa—sarcoma	0.00401	0.00401	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dactinomycin—sarcoma	0.00398	0.00398	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—sarcoma	0.00392	0.00392	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Vincristine—sarcoma	0.00391	0.00391	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Mitoxantrone—sarcoma	0.0039	0.0039	CcSEcCtD
Lisdexamfetamine—Somnolence—Mitoxantrone—sarcoma	0.00389	0.00389	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Vincristine—sarcoma	0.00388	0.00388	CcSEcCtD
Lisdexamfetamine—Fatigue—Vincristine—sarcoma	0.00388	0.00388	CcSEcCtD
Lisdexamfetamine—Convulsion—Etoposide—sarcoma	0.00387	0.00387	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Mitoxantrone—sarcoma	0.00385	0.00385	CcSEcCtD
Lisdexamfetamine—Hypertension—Etoposide—sarcoma	0.00385	0.00385	CcSEcCtD
Lisdexamfetamine—Constipation—Vincristine—sarcoma	0.00384	0.00384	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—sarcoma	0.00384	0.00384	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Mitoxantrone—sarcoma	0.00381	0.00381	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Epirubicin—sarcoma	0.00379	0.00379	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—sarcoma	0.00378	0.00378	CcSEcCtD
Lisdexamfetamine—Fatigue—Mitoxantrone—sarcoma	0.00377	0.00377	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00377	0.00377	CcSEcCtD
Lisdexamfetamine—Constipation—Mitoxantrone—sarcoma	0.00374	0.00374	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.00374	0.00374	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Thiotepa—sarcoma	0.00373	0.00373	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Dactinomycin—sarcoma	0.00371	0.00371	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Etoposide—sarcoma	0.00364	0.00364	CcSEcCtD
Lisdexamfetamine—Asthenia—Thiotepa—sarcoma	0.00364	0.00364	CcSEcCtD
Lisdexamfetamine—Asthenia—Dactinomycin—sarcoma	0.00361	0.00361	CcSEcCtD
Lisdexamfetamine—Tachycardia—Etoposide—sarcoma	0.00355	0.00355	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Vincristine—sarcoma	0.00355	0.00355	CcSEcCtD
Lisdexamfetamine—Skin disorder—Etoposide—sarcoma	0.00354	0.00354	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Etoposide—sarcoma	0.00352	0.00352	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—sarcoma	0.00351	0.00351	CcSEcCtD
Lisdexamfetamine—Urticaria—Mitoxantrone—sarcoma	0.00348	0.00348	CcSEcCtD
Lisdexamfetamine—Anorexia—Etoposide—sarcoma	0.00347	0.00347	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Thiotepa—sarcoma	0.00347	0.00347	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Mitoxantrone—sarcoma	0.00346	0.00346	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.00346	0.00346	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dactinomycin—sarcoma	0.00344	0.00344	CcSEcCtD
Lisdexamfetamine—Dizziness—Thiotepa—sarcoma	0.00335	0.00335	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vincristine—sarcoma	0.00331	0.00331	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—sarcoma	0.00327	0.00327	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—sarcoma	0.00325	0.00325	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Etoposide—sarcoma	0.00325	0.00325	CcSEcCtD
Lisdexamfetamine—Somnolence—Etoposide—sarcoma	0.00324	0.00324	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Mitoxantrone—sarcoma	0.00323	0.00323	CcSEcCtD
Lisdexamfetamine—Asthenia—Vincristine—sarcoma	0.00323	0.00323	CcSEcCtD
Lisdexamfetamine—Vomiting—Thiotepa—sarcoma	0.00322	0.00322	CcSEcCtD
Lisdexamfetamine—Vomiting—Dactinomycin—sarcoma	0.0032	0.0032	CcSEcCtD
Lisdexamfetamine—Rash—Thiotepa—sarcoma	0.0032	0.0032	CcSEcCtD
Lisdexamfetamine—Dermatitis—Thiotepa—sarcoma	0.00319	0.00319	CcSEcCtD
Lisdexamfetamine—Headache—Thiotepa—sarcoma	0.00318	0.00318	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00317	0.00317	CcSEcCtD
Lisdexamfetamine—Rash—Dactinomycin—sarcoma	0.00317	0.00317	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Etoposide—sarcoma	0.00317	0.00317	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Etoposide—sarcoma	0.00314	0.00314	CcSEcCtD
Lisdexamfetamine—Asthenia—Mitoxantrone—sarcoma	0.00314	0.00314	CcSEcCtD
Lisdexamfetamine—Fatigue—Etoposide—sarcoma	0.00314	0.00314	CcSEcCtD
Lisdexamfetamine—Constipation—Etoposide—sarcoma	0.00311	0.00311	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vincristine—sarcoma	0.00308	0.00308	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—sarcoma	0.00303	0.00303	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—sarcoma	0.00302	0.00302	CcSEcCtD
Lisdexamfetamine—Nausea—Thiotepa—sarcoma	0.00301	0.00301	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—sarcoma	0.003	0.003	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mitoxantrone—sarcoma	0.003	0.003	CcSEcCtD
Lisdexamfetamine—Nausea—Dactinomycin—sarcoma	0.00299	0.00299	CcSEcCtD
Lisdexamfetamine—Dizziness—Vincristine—sarcoma	0.00297	0.00297	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.00294	0.00294	CcSEcCtD
Lisdexamfetamine—Urticaria—Etoposide—sarcoma	0.00289	0.00289	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Etoposide—sarcoma	0.00288	0.00288	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—sarcoma	0.00287	0.00287	CcSEcCtD
Lisdexamfetamine—Vomiting—Vincristine—sarcoma	0.00286	0.00286	CcSEcCtD
Lisdexamfetamine—Rash—Vincristine—sarcoma	0.00283	0.00283	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vincristine—sarcoma	0.00283	0.00283	CcSEcCtD
Lisdexamfetamine—Headache—Vincristine—sarcoma	0.00282	0.00282	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—sarcoma	0.0028	0.0028	CcSEcCtD
Lisdexamfetamine—Vomiting—Mitoxantrone—sarcoma	0.00278	0.00278	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—sarcoma	0.00277	0.00277	CcSEcCtD
Lisdexamfetamine—Rash—Mitoxantrone—sarcoma	0.00276	0.00276	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mitoxantrone—sarcoma	0.00276	0.00276	CcSEcCtD
Lisdexamfetamine—Headache—Mitoxantrone—sarcoma	0.00274	0.00274	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—sarcoma	0.00272	0.00272	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—sarcoma	0.00269	0.00269	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Etoposide—sarcoma	0.00268	0.00268	CcSEcCtD
Lisdexamfetamine—Nausea—Vincristine—sarcoma	0.00267	0.00267	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—sarcoma	0.00267	0.00267	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—sarcoma	0.00266	0.00266	CcSEcCtD
Lisdexamfetamine—Asthenia—Etoposide—sarcoma	0.00261	0.00261	CcSEcCtD
Lisdexamfetamine—Nausea—Mitoxantrone—sarcoma	0.0026	0.0026	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—sarcoma	0.0026	0.0026	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—sarcoma	0.00259	0.00259	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—sarcoma	0.00256	0.00256	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—sarcoma	0.00252	0.00252	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—sarcoma	0.00251	0.00251	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—sarcoma	0.0025	0.0025	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Etoposide—sarcoma	0.00249	0.00249	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—sarcoma	0.00248	0.00248	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—sarcoma	0.00247	0.00247	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—sarcoma	0.00243	0.00243	CcSEcCtD
Lisdexamfetamine—Dizziness—Etoposide—sarcoma	0.00241	0.00241	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—sarcoma	0.0024	0.0024	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—sarcoma	0.0024	0.0024	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—sarcoma	0.00236	0.00236	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—sarcoma	0.00233	0.00233	CcSEcCtD
Lisdexamfetamine—Vomiting—Etoposide—sarcoma	0.00232	0.00232	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—sarcoma	0.00231	0.00231	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—sarcoma	0.0023	0.0023	CcSEcCtD
Lisdexamfetamine—Rash—Etoposide—sarcoma	0.0023	0.0023	CcSEcCtD
Lisdexamfetamine—Dermatitis—Etoposide—sarcoma	0.00229	0.00229	CcSEcCtD
Lisdexamfetamine—Headache—Etoposide—sarcoma	0.00228	0.00228	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—sarcoma	0.00225	0.00225	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—sarcoma	0.00221	0.00221	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—sarcoma	0.00218	0.00218	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—sarcoma	0.00217	0.00217	CcSEcCtD
Lisdexamfetamine—Nausea—Etoposide—sarcoma	0.00216	0.00216	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—sarcoma	0.00216	0.00216	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—sarcoma	0.00213	0.00213	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—sarcoma	0.00212	0.00212	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00211	0.00211	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—sarcoma	0.00208	0.00208	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—sarcoma	0.00205	0.00205	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—sarcoma	0.00204	0.00204	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—sarcoma	0.00201	0.00201	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—sarcoma	0.002	0.002	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—sarcoma	0.002	0.002	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—sarcoma	0.00199	0.00199	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—sarcoma	0.00197	0.00197	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—sarcoma	0.00196	0.00196	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00196	0.00196	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—sarcoma	0.00195	0.00195	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—sarcoma	0.00193	0.00193	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—sarcoma	0.00189	0.00189	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—sarcoma	0.00185	0.00185	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—sarcoma	0.00185	0.00185	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—sarcoma	0.00184	0.00184	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—sarcoma	0.00183	0.00183	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—sarcoma	0.00183	0.00183	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—sarcoma	0.00182	0.00182	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—sarcoma	0.00181	0.00181	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—sarcoma	0.0018	0.0018	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—sarcoma	0.0018	0.0018	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—sarcoma	0.00177	0.00177	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—sarcoma	0.00176	0.00176	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—sarcoma	0.00176	0.00176	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—sarcoma	0.00175	0.00175	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—sarcoma	0.00171	0.00171	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Doxorubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—sarcoma	0.00166	0.00166	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Doxorubicin—sarcoma	0.00164	0.00164	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00163	0.00163	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—sarcoma	0.00163	0.00163	CcSEcCtD
Lisdexamfetamine—Urticaria—Epirubicin—sarcoma	0.00162	0.00162	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—sarcoma	0.00162	0.00162	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—sarcoma	0.00161	0.00161	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Epirubicin—sarcoma	0.0015	0.0015	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—sarcoma	0.0015	0.0015	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—sarcoma	0.00149	0.00149	CcSEcCtD
Lisdexamfetamine—Asthenia—Epirubicin—sarcoma	0.00146	0.00146	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Epirubicin—sarcoma	0.0014	0.0014	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—sarcoma	0.00139	0.00139	CcSEcCtD
Lisdexamfetamine—Asthenia—Doxorubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—sarcoma	0.00135	0.00135	CcSEcCtD
Lisdexamfetamine—Vomiting—Epirubicin—sarcoma	0.0013	0.0013	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Lisdexamfetamine—Rash—Epirubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—sarcoma	0.00128	0.00128	CcSEcCtD
Lisdexamfetamine—Dizziness—Doxorubicin—sarcoma	0.00125	0.00125	CcSEcCtD
Lisdexamfetamine—Nausea—Epirubicin—sarcoma	0.00121	0.00121	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—sarcoma	0.0012	0.0012	CcSEcCtD
Lisdexamfetamine—Rash—Doxorubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Lisdexamfetamine—Headache—Doxorubicin—sarcoma	0.00118	0.00118	CcSEcCtD
Lisdexamfetamine—Nausea—Doxorubicin—sarcoma	0.00112	0.00112	CcSEcCtD
